PBP announces opening of vaccine center in South Korea

Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with operations in the USA and South Korea, is pleased to announce the grand opening of its global-scale Vaccine Center in Osong, South Korea.

The opening ceremony was held recently at the Vaccine Center in Osong Campus. The ceremony was attended by many distinguished guests including Minister for Government Policy Coordination Mr Yun-cheol Koo, Deputy Governor Mr Il-hong Seong of Chungbuk Province, Mayor of Cheongju City Mr Beom-deok Han, Representatives from Octava Fund Limited Mr Joseph Tey and Mr Sze Khai Pang.

PBP commenced construction of its Vaccine Center in April this year and completed the global-scale manufacturing facility with a total area of 10,342.88 m2 and a total capacity of 104,000 litres (52 units of 2,000-liter bioreactors) in only eight months by employing Prestige Biologics (334970: KOSDAQ)’ proprietary engineering technology, ALITA Smart BioFactoryTM. With the ALITA system which provides combined advantages of Stainless Steel & Single-Use system, different types of vaccines can be produced in versatile custom manufacturing suites. The Vaccine Center’s Single-Use bioreactors also enhance operational efficiency and productivity while minimizing the risk of cross-contamination.

PBP is currently focusing on two COVID19 vaccine projects to produce Sputnik V and Sputnik Light vaccines. PBP’s global-scale Vaccine Center is capable of producing around 2.6 billion doses of the first dose of Sputnik V vaccine (Ad26 adenovirus vector) per year.

The center will soon be prepared to produce other types of vaccines including mRNA vaccines to actively respond to the growing demands of COVID19 vaccines.

The company ultimately aims to develop its own vaccine products to combat potential future pandemics and PBP Vaccine Center will be the basecamp for this journey.

Previous articleJVPC and PVEP sign MoU
Next articleTsingtuo Group to set up stainless steel wide plates